The patent's first dose was around September 2022 at another location/Moderna Monovalent was administered to a patient yesterday, 18Jan3023.; No adverse event; Pharmacist reporting that Moderna Monovalent was administered to a patient yesterday, 18Jan3023. After giving the vaccine, they realized the vaccine was used beyond use by date of 06Jan2023.; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Pharmacist reporting that Moderna Monovalent was administered to a patient yesterday, 18Jan3023. After giving the vaccine, they realized the vaccine was used beyond use by date of 06Jan2023.), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (The patent's first dose was around September 2022 at another location/Moderna Monovalent was administered to a patient yesterday, 18Jan3023.) and NO ADVERSE EVENT (No adverse event) in a 37-year-old male patient who received mRNA-1273 (Spikevax) (batch no. 044C22A) for COVID-19 prophylaxis.     Patient had No known allergies.  Previously administered products included for COVID-19 prophylaxis: Spikevax in September 2022. Past adverse reactions to the above products included No adverse reaction with Spikevax.    On 18-Jan-2023, the patient received second dose of mRNA-1273 (Spikevax) (unknown route) 1 dosage form. On 18-Jan-2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (Pharmacist reporting that Moderna Monovalent was administered to a patient yesterday, 18Jan3023. After giving the vaccine, they realized the vaccine was used beyond use by date of 06Jan2023.). On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (The patent's first dose was around September 2022 at another location/Moderna Monovalent was administered to a patient yesterday, 18Jan3023.) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Pharmacist reporting that Moderna Monovalent was administered to a patient yesterday, 18Jan3023. After giving the vaccine, they realized the vaccine was used beyond use by date of 06Jan2023.), INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (The patent's first dose was around September 2022 at another location/Moderna Monovalent was administered to a patient yesterday, 18Jan3023.) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Spikevax) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Pharmacist reporting that Moderna Monovalent was administered to a patient yesterday, 18Jan3023. After giving the vaccine, they realized the vaccine was used beyond use by date of 06Jan2023.) and INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (The patent's first dose was around September 2022 at another location/Moderna Monovalent was administered to a patient yesterday, 18Jan3023.).    No concomitant medications were reported. Pharmacist reported that Moderna Monovalent was administered to a patient on18-Jan-2023. It was unknown if patient received any other vaccine 4 weeks prior to COVID-19 vaccine. After administering the vaccine, they realized that the vaccine was used beyond use by date of 06-Jan-2023. Dose administered after 30-day use by date or after manufacturer expiry date. The patent received first dose around September 2022 at another location. The reports mentioned about vial and the vial size was 5.5mL. The vial was initially stored in the refrigerator on 07-Dec-2022. It was reported that the vial did not undergo temperature excursions. No treatment information was reported.